An observational study in Acute Kidney Injury and Acute Kidney Injury (AKI), sponsored by Universitätsklinikum Hamburg-Eppendorf. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Universitätsklinikum Hamburg-Eppendorf · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 109 studies in Acute Kidney Injury with a site in Germany — 21 open to participants now, 24 under way, 1 of them phase 3. Acute Kidney Injury · Germany.
Among the 109 studies in Acute Kidney Injury with a site in Germany, this one is the 6th largest by planned enrollment of the 47 observational ones that give a count, is one of 8 that started in 2025, is one of 47 observational ones, reaches primary completion later than 8 of the 23 other live ones, and was the 100th registered.
1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.
Browse Acute Kidney Injury studies →21 of the 109 studies in Acute Kidney Injury with a site in Germany are open now. Recruiting first, the newest first:
University of Erlangen-Nürnberg Medical School · Sites in Germany
Ages 18+
Universität Münster · Sites in Germany
Ages 18+
AstraZeneca · Sites in Germany, United States, Argentina and 11 more countries
Ages 18–80
Fresenius Medical Care Deutschland GmbH · Sites in Germany, Czechia
Ages up to 18
Universität Münster · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
109 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 7 · Phase 4 4
First in 2002; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 160 across 814 observational studies indexed under Acute Kidney Injury.
Median enrollment 112 across the 62 interventional studies, 120 across the 47 observational. Of the 67 that completed or were terminated, 10 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 109 have an industry lead sponsor. The 10 most frequent:
Universitätsklinikum Hamburg-Eppendorf is the lead sponsor of 416 studies on the registry; 86 are open to participants now.
Universitätsklinikum Hamburg-Eppendorf has 4 studies filed under Acute Kidney Injury — fewer than ten, so there is no comparison to draw.
9 of the studies in Acute Kidney Injury with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06615102Phase 3Universität MünsterReducing Cardiac-surgery Associated Acute Kidney Injury Occurence by Administering Angiotensin II | 2027-01 |
| NCT07579390Helsinki University Central HospitalEffects of Sedation, TEmperature and Pressure After Cardiac Arrest and REsuscitation on Major Adverse Kidney Events (STEPCARE-MAKE) | 2026-12 |
| NCT06180551Universität des SaarlandesHomburg Renal Evaluation Study on the Clinical Utility of Early AKI Diagnosis | 2026-12 |
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
| NCT06772025BayerA Study to Understand How Cardiac Surgery-associated Acute Kidney Injury Develops in Participants Who Undergo Heart Surgery With the Use of Heart-lung Machine | 2027-01-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 109 studies in Acute Kidney Injury with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Hamburg Acute Kidney Injury Study (HAKIS) is a prospective observational cohort study aimed at investigating the mechanisms, risk factors, and clinical determinants of acute kidney injury (AKI) trajectories and consequences.
The Hamburg Acute Kidney Injury Study (HAKIS) is a prospective observational cohort study that includes hospitalized adults (≥18 years) at the time of acute kidney injury (AKI). Potential participants are identified during hospital care, and a structured IT-supported clinical screening system helps detect AKI cases in real time. In parallel, a control group of hospitalized adults with acute illness who have not developed AKI is enrolled to enable comparative analyses of specific risk factors, pathophysiology, and outcomes. All participants undergo a standardized clinical assessment of kidney function, comorbidities, hemodynamic status, medication exposure, procedures, and laboratory parameters. The study includes serial collection of clinical data and biosamples (blood and urine) at study inclusion, during hospitalization, and at 3-month after discharge. All biospecimens are processed within a harmonized pipeline and stored in the Hamburg and European Renal Omics-Biobank (HERO). Beyond the identification of clinical determinants of AKI trajectories, the central objective of HAKIS is to identify biological pathways of sustained kidney injury and repair, improve risk stratification, evaluated prognostic biomarkers, and support the development of precision medicine approaches in post AKI care. Long-term outcomes including progressive chronic kidney disease, cardiovascular events, hospital readmissions, and mortality are collected through annual structured follow-ups. No experimental interventions are performed and all clinical management follows standard of care.
The criteria were revised on the registry on Oct 1, 2026. See what changed
Hospitalized individuals with acute kidney injury (AKI) or at risk for AKI will be identified during routine medical care and invited for study participation. Routine clinical identification of AKI includes an IT-based screening system.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group consists of adult hospitalized individuals, who meet the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) criteria for acute kidney injury (AKI). Participants will be prospectively followed for clinical course, kidney function, biomarker analysis, and outcomes. No experimental interventions are performed. All care follows standard clinical practice.
Group consists of adult hospitalized individuals with an acute illness, who have not developed acute kidney injury (AKI). Participants will be prospectively followed for clinical course, kidney function, biomarker analysis, and outcomes. No experimental interventions are performed. All care follows standard clinical practice.
Kidney Function Recovery after AKI
Improvement of kidney function after acute kidney injury, defined by partial or complete return of the kidney function toward baseline values
Time frame: assessed at discharge, 3-months after discharge, and annual follow-up
Persistent Kidney Function Decline
Sustained impairment of kidney function following acute kidney injury, characterized by incomplete recovery and persistently reduced kidney function over follow-up.
Time frame: assessed at discharge, 3-months after discharge, and annual follow-up
Development or Progression of Chronic Kidney Disease
New onset or worsening of chronic kidney disease during follow-up, assessed based on changes in kidney function over time.
Time frame: assessed at 3-months after discharge, and annual follow-up
End-stage kidney disease (ESKD)
Occurrence of ESKD, characterized by the initiation of maintenance kidney replacement therapy, kidney transplantation or a persistent eGFR \< 15 ml/min/1.73m2
Time frame: assessed at discharge, 3-months after discharge, and annual follow-up
Renal mortality
Death attributable to kidney-related causes as determined by medical record review.
Time frame: assessed at discharge, 3-months after discharge, and annual follow-up
Cardiovascular Outcomes
cardiovascular death, myocardial infarction, heart failure, arrhythmia, stroke
Time frame: assessed at discharge, 3-months after discharge, and annual follow-up
Incidence of vascular diseases
Occurrence of vascular disease, including coronary artery disease, peripheral artery disease, or cerebrovascular disease after AKI
Time frame: assessed at discharge, 3 months after discharge, and annual follow-up
Incidence of Dementia
New diagnosis of dementia occurring during follow-up after AKI
Time frame: assessed at discharge, 3 months after discharge, and annual follow-up
Incidence of Cancer
New diagnosis of malignant disease occurring during follow-up after AKI
Time frame: assessed at discharge, 3 months after discharge, and annual follow-up
Incidence of Infections
New diagnosis of infections occurring during follow-up after AKI
Time frame: assessed at discharge, 3 months after discharge, and annual follow-up
Incidence of psychosomatic or Psychiatric Disorders
New diagnosis of psychosomatic or psychiatric disorders occurring during follow-up after AKI
Time frame: assessed at discharge, 3 months after discharge, and annual follow-up
Started Sep 2025 (actual). Primary completion is estimated for Sep 2026, 12 months after the start.
Of 350 non-industry observational studies under Acute Kidney Injury, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 12 months is below that.
Counting every sponsor, half of 365 studies reached it within 24 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitätsklinikum Hamburg-Eppendorf →